Logo image of CJET

CHIJET MOTOR CO INC (CJET) Stock Fundamental Analysis

NASDAQ:CJET - Nasdaq - KYG4465R1112 - Common Stock - Currency: USD

1.79  -0.04 (-2.19%)

After market: 1.61 -0.18 (-10.06%)

Fundamental Rating

0

Taking everything into account, CJET scores 0 out of 10 in our fundamental rating. CJET was compared to 40 industry peers in the Automobiles industry. CJET has a bad profitability rating. Also its financial health evaluation is rather negative. CJET does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CJET has reported negative net income.
CJET had a negative operating cash flow in the past year.
CJET Yearly Net Income VS EBIT VS OCF VS FCFCJET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

CJET has a Return On Assets of -13.61%. This is comparable to the rest of the industry: CJET outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -13.61%
ROE N/A
ROIC N/A
ROA(3y)-5.94%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CJET Yearly ROA, ROE, ROICCJET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -100 -200 -300 -400 -500

1.3 Margins

CJET does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CJET Yearly Profit, Operating, Gross MarginsCJET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CJET does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CJET has less shares outstanding
CJET has a worse debt/assets ratio than last year.
CJET Yearly Shares OutstandingCJET Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
CJET Yearly Total Debt VS Total AssetsCJET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

CJET has an Altman-Z score of -2.54. This is a bad value and indicates that CJET is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CJET (-2.54) is worse than 63.16% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.54
ROIC/WACCN/A
WACC3.24%
CJET Yearly LT Debt VS Equity VS FCFCJET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 0.15 indicates that CJET may have some problems paying its short term obligations.
The Current ratio of CJET (0.15) is worse than 94.74% of its industry peers.
A Quick Ratio of 0.12 indicates that CJET may have some problems paying its short term obligations.
CJET has a worse Quick ratio (0.12) than 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.12
CJET Yearly Current Assets VS Current LiabilitesCJET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

CJET shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -127083.80%.
EPS 1Y (TTM)-127083.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%30.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CJET Yearly Revenue VS EstimatesCJET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2M 4M 6M 8M
CJET Yearly EPS VS EstimatesCJET Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CJET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CJET Price Earnings VS Forward Price EarningsCJET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CJET Per share dataCJET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CJET!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHIJET MOTOR CO INC

NASDAQ:CJET (2/21/2025, 8:09:33 PM)

After market: 1.61 -0.18 (-10.06%)

1.79

-0.04 (-2.19%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap12.60M
AnalystsN/A
Price TargetN/A
Short Float %4.97%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.72
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS1.35
BVpS-21.87
TBVpS-57.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.94%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.67%
Cap/Sales 15.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.12
Altman-Z -2.54
F-Score5
WACC3.24%
ROIC/WACCN/A
Cap/Depr(3y)14.71%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127083.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%30.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9017.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3878.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3410.26%
OCF growth 3YN/A
OCF growth 5YN/A